Botrops derived hemocoagulase formulation a probable agent for diabetic wound healing

Abstract

Botroclot is a marketed preparation containing hemocoagulase, which is an enzyme having coagulant activity, isolated from the snake Botrops atrox. This formulation is used in dental surgeries and other minor surgical wounds. However, the formulation remains untested in diabetic wounds. Hence, we proposed a study for the topical application of Botroclot in high-fat diet (HFD) + Streptozotocin (STZ) induced diabetic rats. HFD was fed initially to rats which facilitates the development of insulin resistance. Thereafter, an injection of STZ (40 mg/kg, i.p.) was given. This resulted in the development of diabetes with elevated fasting glucose and impaired glucose tolerance. After stabilization of blood glucose values, wounds were created by punch biopsy on the dorsal side of the palm of the rat to mimic the diabetic wounds frequently seen in the case of humans. Later, the application of Botroclot on these wounds was carried out for 15 days. Topical application of hemocoagulase improved the wound closure and there was a gradual decrease in inflammatory markers and a substantial increase in collagen deposition occurred. Histopathological findings indicated the same, with an increase in granulation tissue suggesting that the topical application moderately improves the wound healing in diabetic rats. We conclude that Botroclot can have a mild to moderate effect in improving collagen deposition and thus wound contraction, improving wound closure in diabetic wounds in rats. This study also establishes the basis for exploration of agents from venom-based sources in diabetic wound healing.

Role of topical hemocoagulase in postoperative wound healing following dentoalveolar extraction

“…It hastens the process of hemostasis which is the first step in wound healing. Studies have illustrated the role of hemocoagulase in improving the collagen content, inducing angiogenesis, enhances epithelialization, increased fibrin deposition and reduced inflammation 10,29 . Commercial formulations of hemocoagulase are available under trade names botroclot, botropase, reptilase etc 10,30,31 .…”

“…Studies have illustrated the role of hemocoagulase in improving the collagen content, inducing angiogenesis, enhances epithelialization, increased fibrin deposition and reduced inflammation 10,29 . Commercial formulations of hemocoagulase are available under trade names botroclot, botropase, reptilase etc 10,30,31 . Several invitro and few invivo studies have, in recent years, demonstrated the role of hemocoagulase in wound healing.…”

“…Several invitro and few invivo studies have, in recent years, demonstrated the role of hemocoagulase in wound healing. Studies have demonstrated the effect of systemic hemocoagulase on human volunteers 10,32,33 . There were 2 randomized controlled trials included in this systematic review and both were split mouth designs.…”

“…Hence, hemocoagulase improves wound healing by reducing bleeding time, increasing cell division and capillary network formation while also serving as an effective hemostatic agent. It is commercially available as injections and topical agents 9,10 . The aim of this systematic review was to analyse the existing literature to compare the effectiveness of topical hemocoagulase used in wound dressing/closure with placebo or conventional dressing/closure technique in aiding postoperative wound healing following dentoalveolar extraction…”

Amelioration of high-fat diet (HFD) + CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: in-silico molecular modelling and in-vivo prediction

“…HFD was prepared as per our previous in-house study and published paper by (Keni et al 2020 ). The diet was composed of fat (58%), protein (25%), and carbohydrate (17%).…”